You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTerazosin
Accession NumberDB01162  (APRD00667)
TypeSmall Molecule
GroupsApproved
DescriptionTerazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
Terazosin
Terazosina
Terazosine
Terazosinum
External Identifiers
  • Abbott 45975
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-terazosintablet10 mgoralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosintablet1 mgoralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosintablet2 mgoralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosintablet5 mgoralDominion Pharmacal2001-10-31Not applicableCanada
Hytrintablet10 mgoralBgp Pharma Ulc1992-12-312016-02-19Canada
Hytrintablet1 mgoralBgp Pharma Ulc1989-12-312016-02-19Canada
Hytrintablet2 mgoralBgp Pharma Ulc1989-12-312016-02-19Canada
Hytrintablet5 mgoralBgp Pharma Ulc1989-12-31Not applicableCanada
Mylan-terazosintablet10 mgoralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosintablet1 mgoralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosintablet2 mgoralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Mylan-terazosintablet5 mgoralMylan Pharmaceuticals Ulc2012-11-092016-06-28Canada
Ntp-terazosintablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosintablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosintablet1 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-terazosintablet2 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-terazosintablet5 mgoralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosintablet1 mgoralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosintablet2 mgoralNu Pharm Inc1998-03-052012-09-04Canada
Nu-terazosin 10 Mg Tabletstablet10 mgoralNu Pharm Inc1998-03-052012-09-04Canada
PHL-terazosintablet10 mgoralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosintablet1 mgoralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosintablet2 mgoralPharmel Inc2004-08-04Not applicableCanada
PHL-terazosintablet5 mgoralPharmel Inc2004-08-04Not applicableCanada
PMS-terazosintablet10 mgoralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosintablet1 mgoralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosintablet2 mgoralPharmascience Inc2001-02-23Not applicableCanada
PMS-terazosintablet5 mgoralPharmascience Inc2001-02-23Not applicableCanada
Ratio-terazosin - Tab 10mgtablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 1mgtablet1 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 2mgtablet2 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Ratio-terazosin - Tab 5mgtablet5 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-312014-09-19Canada
Riva-terazosin 1 Mg Tabletstablet1 mgoralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 10 Mg Tabletstablet10 mgoralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 2 Mg Tabletstablet2 mgoralLaboratoire Riva Inc1999-08-312003-07-28Canada
Riva-terazosin 5 Mg Tabletstablet5 mgoralLaboratoire Riva Inc1999-08-312003-07-28Canada
Terazosintablet2 mgoralSanis Health Inc2010-05-12Not applicableCanada
Terazosintablet5 mgoralSanis Health Inc2010-05-12Not applicableCanada
Terazosintablet10 mgoralSanis Health Inc2010-05-12Not applicableCanada
Terazosintablet1 mgoralSanis Health Inc2010-05-12Not applicableCanada
Terazosin-1tablet1 mgoralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-10tablet10 mgoralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-2tablet2 mgoralPro Doc Limitee1998-06-02Not applicableCanada
Terazosin-5tablet5 mgoralPro Doc Limitee1998-06-02Not applicableCanada
Teva-terazosintablet1 mgoralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosintablet2 mgoralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosintablet5 mgoralTeva Canada Limited1998-02-09Not applicableCanada
Teva-terazosintablet10 mgoralTeva Canada Limited1998-02-09Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-terazosintablet5 mgoralApotex Inc1997-09-26Not applicableCanada
Apo-terazosintablet10 mgoralApotex Inc1997-09-26Not applicableCanada
Apo-terazosintablet1 mgoralApotex Inc1997-09-26Not applicableCanada
Apo-terazosintablet2 mgoralApotex Inc1997-09-26Not applicableCanada
Tarazosincapsule1 mg/1oralMylan Institutional Inc.2000-04-01Not applicableUs
Tarazosincapsule2 mg/1oralMylan Institutional Inc.2000-04-01Not applicableUs
Tarazosincapsule5 mg/1oralMylan Institutional Inc.2000-04-01Not applicableUs
Terazosincapsule10 mg/1oralREMEDYREPACK INC.2013-09-19Not applicableUs
Terazosincapsule10 mg/1oralbryant ranch prepack2004-12-21Not applicableUs
Terazosincapsule1 mg/1oralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
Terazosincapsule1 mg/1oralApotex Corp.2001-04-12Not applicableUs
Terazosincapsule1 mg/1oralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
Terazosincapsule10 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Terazosincapsule5 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
Terazosincapsule5 mg/1oralProficient Rx LP2004-12-20Not applicableUs
Terazosincapsule1 mg/1oralREMEDYREPACK INC.2014-05-07Not applicableUs
Terazosincapsule2 mg/1oralApotex Corp.2001-04-12Not applicableUs
Terazosincapsule10 mg/1oralProficient Rx LP2004-12-21Not applicableUs
Terazosincapsule2 mg/1oralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
Terazosincapsule2 mg/1oralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
Terazosincapsule5 mg/1oralPreferred Pharmaceuticals, Inc.2013-07-12Not applicableUs
Terazosincapsule2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-30Not applicableUs
Terazosincapsule10 mg/1oralAidarex Pharmaceuticals LLC2001-04-12Not applicableUs
Terazosincapsule1 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Terazosincapsule5 mg/1oralApotex Corp.2001-04-12Not applicableUs
Terazosincapsule5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2004-12-20Not applicableUs
Terazosincapsule5 mg/1oralREMEDYREPACK INC.2013-09-19Not applicableUs
Terazosincapsule5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-03Not applicableUs
Terazosincapsule2 mg/1oralNorthwind Pharmaceuticals, LLC2015-02-27Not applicableUs
Terazosincapsule10 mg/1oralApotex Corp.2001-04-12Not applicableUs
Terazosincapsule10 mg/1oralJubilant Cadista Pharmaceuticals Inc.2004-12-21Not applicableUs
Terazosincapsule2 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-06-09Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralCardinal Health2009-11-02Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralSandoz Inc1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-08-16Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralSTAT Rx USA LLC2004-12-20Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralPhysicians Total Care, Inc.2000-08-29Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralSandoz Inc1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralREMEDYREPACK INC.2011-07-01Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralCardinal Health2009-11-02Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-05-17Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralREMEDYREPACK INC.2013-05-132016-04-05Us
Terazosin Hydrochloridecapsule10 mg/1oralPhysicians Total Care, Inc.2000-08-29Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralbryant ranch prepack2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-20Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralSandoz Inc1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralREMEDYREPACK INC.2011-07-28Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralREMEDYREPACK INC.2011-11-10Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralUnit Dose Services1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralREMEDYREPACK INC.2010-11-10Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralPhysicians Total Care, Inc.2003-06-02Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralbryant ranch prepack2004-12-20Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralREMEDYREPACK INC.2011-07-29Not applicableUs
Terazosin Hydrochloridecapsule1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule10 mg/1oralAphena Pharma Solutions Tennessee, Llc2004-12-21Not applicableUs
Terazosin Hydrochloridecapsule10 mg/1oralSandoz Inc1998-03-30Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralPhysicians Total Care, Inc.2000-09-05Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Terazosin Hydrochloridecapsule2 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule10 mg/1oralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule1 mg/1oralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule2 mg/1oralPd Rx Pharmaceuticals, Inc.2013-02-22Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule1 mg/1oralCardinal Health2011-01-28Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule2 mg/1oralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule5 mg/1oralCardinal Health2011-01-28Not applicableUs
Terazosin Hydrochloride Anhydrouscapsule5 mg/1oralMylan Pharmaceuticals Inc.2000-02-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BlavinBaliarda (Argentina)
FlumarcRaffo (Argentina)
FosfomicFinadiet (Argentina)
HeitrinAbbott (Germany; discontinued)
HytrinexAmdipharm (Sweden)
ItrinKeryos (Italy)
UrodieKeryos (Italy)
VicardAmdipharm (Austria)
ZayaselNot Available
Brand mixtures
NameLabellerIngredients
Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgAbbott Laboratories, Limited
Salts
Name/CASStructureProperties
Terazosin Hydrochloride
Thumb
  • InChI Key: IWSWDOUXSCRCKW-UHFFFAOYNA-N
  • Monoisotopic Mass: 423.167332052
  • Average Mass: 423.894
DBSALT000326
Categories
UNII8L5014XET7
CAS number63590-64-7
WeightAverage: 387.4329
Monoisotopic: 387.190654313
Chemical FormulaC19H25N5O4
InChI KeyInChIKey=VCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
IUPAC Name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Saccharide
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Oxolane
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of symptomatic BPH and mild to moderate hypertension.
PharmacodynamicsTerazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.
Mechanism of actionIn general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Terazosin is the first α1-receptor antagonist to demonstrate selectivity for the α1A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting α1A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.
Related Articles
AbsorptionEssentially completely absorbed in man (90% bioavailability).
Volume of distributionNot Available
Protein binding90-94%
Metabolism

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.

Route of eliminationApproximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.
Half life12 hours
ClearanceNot Available
ToxicityLD50=259.3mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9646
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.698
P-glycoprotein inhibitor INon-inhibitor0.5666
P-glycoprotein inhibitor IINon-inhibitor0.8619
Renal organic cation transporterNon-inhibitor0.6319
CYP450 2C9 substrateNon-substrate0.8864
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateSubstrate0.7753
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9435
CYP450 2D6 inhibitorNon-inhibitor0.9628
CYP450 2C19 inhibitorNon-inhibitor0.9492
CYP450 3A4 inhibitorNon-inhibitor0.7905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.901
Ames testNon AMES toxic0.5943
CarcinogenicityNon-carcinogens0.906
BiodegradationNot ready biodegradable0.9785
Rat acute toxicity2.2262 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8368
hERG inhibition (predictor II)Inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit; tabletoral
Capsuleoral1 mg/1
Capsuleoral10 mg/1
Capsuleoral2 mg/1
Capsuleoral5 mg/1
Tabletoral1 mg
Tabletoral10 mg
Tabletoral2 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Hytrin 10 mg Tablet1.85USD tablet
Terazosin HCl 1 mg capsule1.67USD capsule
Terazosin HCl 10 mg capsule1.67USD capsule
Terazosin HCl 2 mg capsule1.67USD capsule
Terazosin HCl 5 mg capsule1.67USD capsule
Hytrin 5 mg Tablet1.26USD tablet
Hytrin 2 mg Tablet0.93USD tablet
Apo-Terazosin 10 mg Tablet0.92USD tablet
Novo-Terazosin 10 mg Tablet0.92USD tablet
Nu-Terazosin 10 mg Tablet0.92USD tablet
Pms-Terazosin 10 mg Tablet0.92USD tablet
Ratio-Terazosin 10 mg Tablet0.92USD tablet
Hytrin 1 mg Tablet0.73USD tablet
Apo-Terazosin 5 mg Tablet0.63USD tablet
Novo-Terazosin 5 mg Tablet0.63USD tablet
Nu-Terazosin 5 mg Tablet0.63USD tablet
Pms-Terazosin 5 mg Tablet0.63USD tablet
Ratio-Terazosin 5 mg Tablet0.63USD tablet
Apo-Terazosin 2 mg Tablet0.46USD tablet
Novo-Terazosin 2 mg Tablet0.46USD tablet
Nu-Terazosin 2 mg Tablet0.46USD tablet
Pms-Terazosin 2 mg Tablet0.46USD tablet
Ratio-Terazosin 2 mg Tablet0.46USD tablet
Apo-Terazosin 1 mg Tablet0.37USD tablet
Novo-Terazosin 1 mg Tablet0.37USD tablet
Nu-Terazosin 1 mg Tablet0.37USD tablet
Pms-Terazosin 1 mg Tablet0.37USD tablet
Ratio-Terazosin 1 mg Tablet0.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5212176 No1993-06-292010-06-29Us
US5294615 No1993-04-292013-04-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point273 °CPhysProp
water solubility29.7mg/mLNot Available
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.5 mg/mLALOGPS
logP1.12ALOGPS
logP1.18ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)19.93ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.04 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability41.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, “Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines.” U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
External Links
ATC CodesG04CA03
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelDownload (1020 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcebutololThe risk or severity of adverse effects can be increased when Terazosin is combined with Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Terazosin.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Terazosin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Terazosin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Terazosin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Terazosin.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Terazosin.
AliskirenThe risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Terazosin.
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Terazosin.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Terazosin.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Terazosin.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Terazosin.
AmlodipineTerazosin may increase the hypotensive activities of Amlodipine.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Terazosin.
AmobarbitalAmobarbital may increase the hypotensive activities of Terazosin.
AmrinoneTerazosin may increase the hypotensive activities of Amrinone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Terazosin is combined with Amyl Nitrite.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Terazosin.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Terazosin.
AripiprazoleAripiprazole may increase the hypotensive activities of Terazosin.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Terazosin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Terazosin.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Terazosin.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Terazosin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Terazosin.
AzelnidipineTerazosin may increase the hypotensive activities of Azelnidipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Terazosin is combined with Azilsartan medoxomil.
AzimilideTerazosin may increase the hypotensive activities of Azimilide.
BarbitalBarbital may increase the hypotensive activities of Terazosin.
BarnidipineTerazosin may increase the hypotensive activities of Barnidipine.
BefunololBefunolol may increase the orthostatic hypotensive activities of Terazosin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Terazosin.
BenidipineTerazosin may increase the hypotensive activities of Benidipine.
BepridilTerazosin may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Terazosin.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Terazosin.
BevantololBevantolol may increase the orthostatic hypotensive activities of Terazosin.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Terazosin.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Terazosin.
BopindololBopindolol may increase the orthostatic hypotensive activities of Terazosin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Terazosin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Terazosin.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Terazosin.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Terazosin.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.
BupranololBupranolol may increase the orthostatic hypotensive activities of Terazosin.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Terazosin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Terazosin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Terazosin.
CanagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Terazosin.
CaptoprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Terazosin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Terazosin.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Terazosin.
CarvedilolCarvedilol may increase the antihypertensive activities of Terazosin.
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Terazosin.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Terazosin.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Terazosin.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Terazosin.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Terazosin.
CilazaprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.
CilnidipineTerazosin may increase the hypotensive activities of Cilnidipine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Terazosin.
CinnarizineTerazosin may increase the hypotensive activities of Cinnarizine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Terazosin.
CirazolineTerazosin may decrease the vasoconstricting activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Terazosin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Terazosin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Terazosin.
ClevidipineTerazosin may increase the hypotensive activities of Clevidipine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Terazosin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Terazosin.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Terazosin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Terazosin.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Terazosin.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Terazosin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Terazosin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Terazosin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Terazosin.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Terazosin.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Terazosin.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Terazosin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Terazosin.
DapagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Terazosin.
DarodipineTerazosin may increase the hypotensive activities of Darodipine.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Terazosin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Terazosin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Terazosin.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Terazosin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Terazosin.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Terazosin.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Terazosin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Terazosin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Terazosin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Terazosin.
DiltiazemTerazosin may increase the hypotensive activities of Diltiazem.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Terazosin.
DinutuximabThe risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Terazosin.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Terazosin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Terazosin.
DotarizineTerazosin may increase the hypotensive activities of Dotarizine.
DoxazosinDoxazosin may increase the antihypertensive activities of Terazosin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Terazosin.
DuloxetineTerazosin may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Terazosin.
EfonidipineTerazosin may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Terazosin.
EmpagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Terazosin.
EperisoneTerazosin may increase the hypotensive activities of Eperisone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Terazosin.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Terazosin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.
ErgotamineTerazosin may decrease the vasoconstricting activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Terazosin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Terazosin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Terazosin.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Terazosin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Terazosin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Terazosin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Terazosin.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Terazosin.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Terazosin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Terazosin.
FelodipineTerazosin may increase the hypotensive activities of Felodipine.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.
FendilineTerazosin may increase the hypotensive activities of Fendiline.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Terazosin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Terazosin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Terazosin.
FlunarizineTerazosin may increase the hypotensive activities of Flunarizine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Terazosin.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.
GabapentinTerazosin may increase the hypotensive activities of Gabapentin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Terazosin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Terazosin.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Terazosin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Terazosin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Terazosin.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Terazosin.
HexobarbitalHexobarbital may increase the hypotensive activities of Terazosin.
HydralazineThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Terazosin.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Terazosin.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Terazosin.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Terazosin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Terazosin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Terazosin.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Terazosin.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.
IndenololIndenolol may increase the orthostatic hypotensive activities of Terazosin.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Terazosin.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Terazosin.
IndoraminTerazosin may increase the antihypertensive activities of Indoramin.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Terazosin.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Terazosin.
IsoxsuprineThe risk or severity of adverse effects can be increased when Terazosin is combined with Isoxsuprine.
IsradipineTerazosin may increase the hypotensive activities of Isradipine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Terazosin.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Terazosin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Terazosin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Terazosin.
LabetalolLabetalol may increase the antihypertensive activities of Terazosin.
LacidipineTerazosin may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Terazosin.
LamotrigineTerazosin may increase the hypotensive activities of Lamotrigine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Terazosin.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Terazosin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Terazosin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Terazosin.
LercanidipineTerazosin may increase the hypotensive activities of Lercanidipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Terazosin.
LevobunololThe risk or severity of adverse effects can be increased when Terazosin is combined with Levobunolol.
LevodopaTerazosin may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Terazosin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Terazosin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Terazosin.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Terazosin.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.
Magnesium SulfateTerazosin may increase the hypotensive activities of Magnesium Sulfate.
ManidipineTerazosin may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.
MephentermineTerazosin may decrease the vasoconstricting activities of Mephentermine.
MetaraminolTerazosin may decrease the vasoconstricting activities of Metaraminol.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Terazosin.
MethohexitalMethohexital may increase the hypotensive activities of Terazosin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Terazosin.
MethoxamineTerazosin may decrease the vasoconstricting activities of Methoxamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Terazosin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Terazosin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Terazosin.
MetipranololThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Terazosin.
MibefradilTerazosin may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Terazosin.
MidodrineTerazosin may decrease the vasoconstricting activities of Midodrine.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Terazosin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Terazosin.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Terazosin.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Terazosin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terazosin.
NadololThe risk or severity of adverse effects can be increased when Terazosin is combined with Nadolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Terazosin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Terazosin.
NebivololThe risk or severity of adverse effects can be increased when Terazosin is combined with Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Terazosin.
NesiritideThe risk or severity of adverse effects can be increased when Terazosin is combined with Nesiritide.
NicardipineTerazosin may increase the hypotensive activities of Nicardipine.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.
NicorandilNicorandil may increase the hypotensive activities of Terazosin.
NifedipineTerazosin may increase the hypotensive activities of Nifedipine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Terazosin.
NiguldipineTerazosin may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Terazosin.
NiludipineTerazosin may increase the hypotensive activities of Niludipine.
NilvadipineTerazosin may increase the hypotensive activities of Nilvadipine.
NimesulideTerazosin may increase the hypotensive activities of Nimesulide.
NimodipineTerazosin may increase the hypotensive activities of Nimodipine.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Terazosin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Terazosin.
NisoldipineTerazosin may increase the hypotensive activities of Nisoldipine.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Terazosin.
NitrendipineTerazosin may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Terazosin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Terazosin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Terazosin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Terazosin.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Terazosin.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Terazosin.
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Terazosin.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Terazosin.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Terazosin.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.
PenbutololThe risk or severity of adverse effects can be increased when Terazosin is combined with Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Terazosin.
PerhexilineTerazosin may increase the hypotensive activities of Perhexiline.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Terazosin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Terazosin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Terazosin.
PhenylephrineTerazosin may decrease the vasoconstricting activities of Phenylephrine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Terazosin.
PinaveriumTerazosin may increase the hypotensive activities of Pinaverium.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Terazosin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Terazosin.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Terazosin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Terazosin.
PractololPractolol may increase the orthostatic hypotensive activities of Terazosin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Terazosin.
PrazosinPrazosin may increase the antihypertensive activities of Terazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Terazosin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Terazosin.
PregabalinTerazosin may increase the hypotensive activities of Pregabalin.
PrenylamineTerazosin may increase the hypotensive activities of Prenylamine.
PrimidonePrimidone may increase the hypotensive activities of Terazosin.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Terazosin.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Terazosin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Terazosin.
QuetiapineThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Terazosin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Terazosin.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Terazosin.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Terazosin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Terazosin.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Terazosin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Terazosin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terazosin.
RiociguatThe risk or severity of adverse effects can be increased when Terazosin is combined with Riociguat.
RisedronateTerazosin may increase the hypotensive activities of Risedronate.
RisperidoneTerazosin may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Terazosin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Terazosin.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Terazosin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Terazosin.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Terazosin.
SecobarbitalSecobarbital may increase the hypotensive activities of Terazosin.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Terazosin.
SildenafilSildenafil may increase the hypotensive activities of Terazosin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.
SilodosinSilodosin may increase the antihypertensive activities of Terazosin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Terazosin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Terazosin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Terazosin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Terazosin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Terazosin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Terazosin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Terazosin.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Terazosin.
TadalafilTadalafil may increase the hypotensive activities of Terazosin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Terazosin.
TamsulosinTamsulosin may increase the antihypertensive activities of Terazosin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Terazosin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Terazosin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Terazosin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Terazosin.
ThiamylalThiamylal may increase the hypotensive activities of Terazosin.
ThiopentalThiopental may increase the hypotensive activities of Terazosin.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Terazosin.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Terazosin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Terazosin.
Tolfenamic AcidTerazosin may increase the hypotensive activities of Tolfenamic Acid.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Terazosin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Terazosin.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Terazosin.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Terazosin.
TranilastTerazosin may increase the hypotensive activities of Tranilast.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Terazosin.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.
TrimazosinTerazosin may increase the antihypertensive activities of Trimazosin.
UdenafilUdenafil may increase the hypotensive activities of Terazosin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Terazosin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Terazosin.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.
VardenafilVardenafil may increase the hypotensive activities of Terazosin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Terazosin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Terazosin.
VerapamilTerazosin may increase the hypotensive activities of Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Terazosin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Terazosin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Terazosin.
XylometazolineTerazosin may increase the hypotensive activities of Xylometazoline.
ZiconotideTerazosin may increase the hypotensive activities of Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Terazosin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Chapple CR: Medical therapy and quality of life. Eur Urol. 1998;34 Suppl 2:10-7; discussion 46. [PubMed:9732824 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700 ]
  4. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
  5. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165 ]
  6. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG: Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001 Nov;58(5):717-22. [PubMed:11711348 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Simpson P: Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985 Jun;56(6):884-94. [PubMed:2988814 ]
  4. Vincent J, Dachman W, Blaschke TF, Hoffman BB: Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8. [PubMed:1358918 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23